Bryan Allinson
Company: Vanquish Bio
Job title: Co-Founder & Chief Executive Officer
Bio:
Bryan has an extensive 20+ year career in healthcare and biotech innovation. In 2020, he co-founded Vanquish Bio to leverage groundbreaking research in natural killer derived extra cellular vesicles. He previously spun-out Lung Therapeutics (LTI) from the University of Texas, served on the LTI’s initial board, and recruited its first CEO (LTI was later acquired by Aileron Therapeutics). He formed Cernostics out of the Geisinger Health System and the University of Pittsburgh to market precision pathology software. He has significant experience in health and biomedical partnering. He served in a leadership role at AdventHealth, and was the chief business officer of the Early Stage Clinical Research Unit (CRU). In this role, he led financing, partnering and operations for 200 cancer trials, including Phase 1, 2, 3, and 4 (outcomes) studies.
Seminars:
Chair’s Closing Remarks 5:20 pm
day: Conference Day One
Panel Discussion: Accelerating Scalable & Cost-Effective Extra-Cellular Vesicle Manufacturing for the Development of Therapeutics for Regenerative, Precision & CGT Therapies 11:30 am
Exploring cost-efficient exosome sources such as bodily fluids to reduce the high production costs associated with cellderived exosomes Understanding the complexities involved in setting up pipelines for the purification and production of engineered exosomes to optimize cost considerations throughout the development process Delving into the factors contributing to the cost of engineered exosomes, including production…Read more
day: Conference Day Two